Analyst Ratings For Augmedix
Portfolio Pulse from Benzinga Insights
Analyst ratings for Augmedix (NASDAQ:AUGX) show a mix of opinions, with recent actions including both upgrades and downgrades. The average 12-month price target is $5.00, with a high of $5.50 and a low of $4.50, marking a 14.24% decline from the previous average. Augmedix's financial performance shows strong revenue growth and net margin, but challenges in asset utilization and higher debt levels. Analysts' ratings and price targets reflect their views on the company's future performance relative to market conditions.

April 09, 2024 | 8:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Augmedix has received mixed analyst ratings with recent updates showing both positive and negative adjustments. The average 12-month price target is now $5.00. The company has shown strong revenue growth but faces challenges in asset utilization and debt management.
The mixed analyst ratings and adjustments in price targets reflect uncertainty and diverse opinions about Augmedix's future performance. The strong revenue growth is a positive sign, but the challenges in asset utilization and higher debt levels may concern investors, leading to a neutral short-term impact on the stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100